Trial Search Results

Single Center Food Allergy Oral Immunotherapy Study

The Primary Objective of the study is to develop a customized regimen for oral immunotherapy that reflects what the subject is allergic in a clinically significant way (i.e., the offending food allergen is defined as a food allergen with a positive skin test or positive specific IgE and a positive DBPCFC). Therefore, the investigators prefer that both single and multiple food allergy subjects are included in the study.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Food proteins


Phase 1


Inclusion Criteria:

   - Moderate to severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic
   subjects between the ages of 4 to 55 years old.

   - Sensitivity to food allergen will be documented by a positive skin prick test result
   (see Appendix for details) or allergen specific ImmunoCAP IgE level with 7 kU/L as a
   lower limit of eligibility.

Exclusion Criteria:

   - No absolute contraindications are known. However, the risk of serious systemic
   anaphylactic reactions to food allergens suggests a number of preexisting conditions
   that should be considered relative contraindications. Among those conditions are acute
   infections, autoimmune disease, severe cardiac disease, and treatment with
   beta-adrenergic antagonistic drugs (beta-blockers).

   - Subjects having a history of severe anaphylaxis to food allergens that will be
   desensitized in this study requiring intubation or admission to an ICU, frequent
   allergic or non-allergic urticaria, or history consistent with poorly controlled
   persistent asthma.

Ages Eligible for Study

4 Years - 55 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305